Literature DB >> 19824041

Antitumor effects of a recombinant pseudotype baculovirus expressing Apoptin in vitro and in vivo.

Yongfei Pan1, Liurong Fang, Huiying Fan, Rui Luo, Qian Zhao, Huanchun Chen, Shaobo Xiao.   

Abstract

Apoptin, a chicken anemia virus-derived, p53-independent, bcl-2-insenstive apoptotic protein with the ability to specifically induce apoptosis in tumor or transformed cells, is a promising tool for cancer gene therapy. In this study, pseudotype baculovirus, a recently developed alternative gene delivery system, was used as a vector to express Apoptin. The resultant recombinant baculovirus (BV-Apoptin) efficiently expressed the Apoptin protein and induced apoptosis in HepG2 and H22 cells. Studies in vivo showed that intratumoral injection of BV-Apoptin into a xenogeneic tumor (derived from H22 murine hepatoma cells in C57BL/6 mice) significantly suppressed tumor growth, and significantly prolonged the survival of tumor-bearing mice compared to a control pseudotype baculovirus that expressed EGFP. Taken together, these results suggest that Apoptin, expressed from the pseudotype baculovirus vector, has the potential to become a therapeutic agent for the treatment of solid tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19824041     DOI: 10.1002/ijc.24959

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Mechanisms of Apoptin-induced cell death.

Authors:  Suna Zhou; Mingxin Zhang; Jia Zhang; Hui Shen; Ermek Tangsakar; Jiansheng Wang
Journal:  Med Oncol       Date:  2011-11-22       Impact factor: 3.064

2.  AdHu5-apoptin induces G2/M arrest and apoptosis in p53-mutated human gastric cancer SGC-7901 cells.

Authors:  Qianqian Li; Hongbin Zhang; Cui Tan; Weiyan Peng; Guosheng Ren; Bei Jia; Ying He; Pilong Wang; Xiangyang Zhou; Tingxiu Xiang
Journal:  Tumour Biol       Date:  2013-06-28

Review 3.  Viral genes as oncolytic agents for cancer therapy.

Authors:  Shishir Kumar Gupta; Ravi Kumar Gandham; A P Sahoo; A K Tiwari
Journal:  Cell Mol Life Sci       Date:  2014-11-19       Impact factor: 9.207

4.  A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.

Authors:  Solmaz Agha Amiri; Soraya Shahhosseini; Najmeh Zarei; Dorsa Khorasanizadeh; Elahe Aminollahi; Faegheh Rezaie; Mehryar Zargari; Mohammad Azizi; Vahid Khalaj
Journal:  AMB Express       Date:  2017-06-02       Impact factor: 3.298

5.  Human serum albumin-mediated apoptin delivery suppresses breast cancer cell growth in vitro and in vivo.

Authors:  Fang Wu; Yizhi Liu; Jian Li; Lei Hou; Fuxi Lei; Shangke Huang; Lu Feng; Xinhan Zhao
Journal:  Oncol Lett       Date:  2016-12-07       Impact factor: 2.967

Review 6.  Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications.

Authors:  Chi-Yuan Chen; Chin-Yu Lin; Guan-Yu Chen; Yu-Chen Hu
Journal:  Biotechnol Adv       Date:  2011-04-28       Impact factor: 14.227

Review 7.  Cancer Treatment Goes Viral: Using Viral Proteins to Induce Tumour-Specific Cell Death.

Authors:  Jasmine Wyatt; Manuel M Müller; Mahvash Tavassoli
Journal:  Cancers (Basel)       Date:  2019-12-07       Impact factor: 6.639

8.  Therapeutic anti-tumor effect of exogenous apoptin driven by human survivin gene promoter in a lentiviral construct.

Authors:  Feng Ye; Bo Zhong; Guorong Dan; Fan Jiang; Yan Sai; Jiqing Zhao; Huiqin Sun; Zhongmin Zou
Journal:  Arch Med Sci       Date:  2013-05-28       Impact factor: 3.318

Review 9.  Baculovirus-mediated gene delivery and RNAi applications.

Authors:  Kaisa-Emilia Makkonen; Kari Airenne; Seppo Ylä-Herttulala
Journal:  Viruses       Date:  2015-04-22       Impact factor: 5.048

10.  Induction of robust immunity response in mice by dual-expression-system-based recombinant baculovirus expressing the capsid protein of porcine circovirus type 2.

Authors:  Yu Ye; Xiaoliang Cheng; Jie Zhang; Tiezhu Tong; Wenyao Lin; Ming Liao; Huiying Fan
Journal:  Virol J       Date:  2013-10-28       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.